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reimbursed for continued use of a therapy. Beneﬁt is evaluated
based on a priori criteria regarding what constitutes a clinically
important improvement. Payers incur costs for the patients
who meet established responder criteria for a given therapy.
METHODS: An economic evaluation of Sativex(r) vs. standard
analgesic care in adults with Multiple Sclerosis and neuropathic
pain is used to illustrate the application of a responder-based
reimbursement scenario (N = 66). Sativex(r) response was
deﬁned as a reduction in pain score (2-points on BS-11) on the
10th day of treatment based on clinician opinion. Base case
and responder-based incremental cost-utility ratios (ICUR) were
determined. Efﬁcacy and safety data were based on a phase III
pivotal trial. Costs (CND$ 2006) were based on provincial
sources. Direct medical resources were taken from a burden of
illness study. RESULTS: In the base case, the incremental cost
was $5339 and incremental QALY was 0.13. The ICUR was
$70,103/QALY. In the responder-based economic analysis,
55.9% of Sativex(r) patients were deﬁned as responders, incre-
mental costs was $9352 and incremental QALY was 0.21, result-
ing in an ICUR of $44,917/QALY. CONCLUSION: Progressive
licensing, in the form of conditional approvals, allows for earlier
market access to pharmaceutical products. Based on the condi-
tional nature of these approvals, the evidence for a new therapy
may not be deﬁnitive. However, their potential beneﬁt, by ﬁlling
a void for previously unmet medical need, is signiﬁcant. As
payers are interested in maximizing value for money, they may
not feel compelled to fund a conditionally-licensed product,
when the data supporting its value is considered uncertain. To
increase the conﬁdence in the value for money proposition,
responder-based reimbursement scenarios may be an option.
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OBJECTIVE: The PROLabels database (www.mapi-prolabels.
org) was developed to provide easy access to patient-reported
outcomes (PROs) included in approved labeling of products in
Europe and the USA. Two years after its launch, the coverage of
FDA labels has been extended to give a more comprehensive
image of the current use of PROs in clinical studies. METHODS:
In 2006, the database opened with drugs approved in Europe
through the centralized procedure established by the EMEA
in January 1995 and with New Molecular Entities (NME)
approved in the USA since January 1998. The extension project
focused on other chemical types approved by FDA (e.g. New
dosage form, New combination, etc.) and on NME approved
before 1998. Once a PRO claim was identiﬁed in a label, the drug
was added in PROLabels and the following information was
retrieved: the PRO claim, description of clinical studies support-
ing the claim, description of PRO endpoints and measures used,
pharmacological action of products and information source.
RESULTS: New ﬁgures resulting from this major extension of
PROLabels will be presented. These new ﬁgures will include the
number of drug products present in the database with the FDA/
EMEA distribution, the most represented therapeutic areas (cur-
rently nervous system diseases: 32.0%, immune system diseases:
24.0%, musculoskeletal diseases: 18.0%, genitourinary system
diseases: 14.8%, and respiratory system diseases: 13.2%), and
the most frequently measured PROs (currently Signs and Symp-
toms followed by Health-Related Quality of Life (HRQL)).
Finally, any change in the rate of PRO data found overall in FDA
approvals will be checked. CONCLUSION: This extension of
the FDA coverage of the PROLabels database allows a clearer
picture of the use of PROs to assess patients’ treatment beneﬁt to
be drawn. In addition, it facilitates the examination of the dis-
crepancies between the US and European regulatory agencies.
CANCER—Clinical Outcomes Studies
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OBJECTIVE: Protein HER2 identiﬁes a more aggressive subtype
of breast cancer. For this type of tumor, currently there are
speciﬁc treatments (trastuzumab and lapatinib), which, if used in
early phase of the disease can render a higher chance of cure and
survival to the patients (the HERA study showed that the use of
Herceptin after a standard chemotherapy in adjuvant tumors has
reduced by 46% the risk of a tumor to return). The study
objective is to assess the performance of the diagnostic tests
of this protein for Brazilian patients with breast cancer.
METHODS: A diary study with 220 Brazilian clinical oncolo-
gists was used; in the end of the study, a total of 3994 patients
with breast cancer were followed up. RESULTS: Fifty-eight
percent of the patients found were in the public market, and 42%
were from the private market. We also have that 64% of the
patients have early tumors (adjuvant or neoadjuvant), and 36%
have metastatic tumors. The HER2 test is performed in 80% of
the patients in the private market, with only 36% of the patients
of the public market being tested. The test performance rate
has little correlation with the disease phase (P value = 0.81);
however, there is some correlation of the performance of this test
with the patient’s age (P value = 0.3). Physicians from several
Brazilian states have different behavior while performing this
exam (P value = 6^162). CONCLUSION: We veriﬁed that few
patients of the public market (36%) perform this test comparing
with the private market (80%). We also veriﬁed great differences
in the performance of it in the different regions of the country. An
increased performance rate of this exam would increase the
chances of survival and cure for the patients, since it allows the
use of speciﬁc treatments for positive HER2 tumors.
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OBJECTIVE: The purpose of this study is to systematically
review the evidence of palonosetron in chemotherapy-induced
nausea and vomiting (CINV) and to understand its place in
therapy. METHODS: The English-language literature in OVID
and Cochrane databases were searched using the following
terms: palonosetron, antiemetics, CINV, and delayed. Of the 168
abstracts identiﬁed, 3 pivotal trials were deemed relevant by 2
independent reviewers. Guidelines from the American Society of
Clinical Oncology, National Comprehensive Cancer Network
(NCCN), and Multinational Association of Supportive Care in
Cancer and the Food and Drug Administration (FDA) reviewers’
comments on palonosetron were also obtained. RESULTS: The
trials, all non-inferiority studies, compared palonosetron
0.25mg to single-dose intravenous ondansetron or dolasetron.
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